The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 1: an overview

BDJ ◽  
2022 ◽  
Author(s):  
Vinod Patel ◽  
Sanford Grossman ◽  
Rana Wali ◽  
Megan Burns ◽  
Sheelen Patel ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Dental Status ◽  
Solid Tumours ◽  
Bone Targeting

scholarly journals Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events

2021 ◽  
Vol 22 (2) ◽  
pp. 243-254
Author(s):  
Fränce Hardtstock ◽  
Zeki Kocaata ◽  
Thomas Wilke ◽  
Axel Dittmar ◽  
Marco Ghiani ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Solid Tumors ◽  
Resource Utilization ◽  
Inpatient Care ◽  
Healthcare Resource ◽  
Cohort Analysis ◽  
Healthcare Resource Utilization ◽  
Bone Targeting ◽  
Skeletal Related Events ◽  
The Impact

Abstract Background This study analyzes the impact of skeletal-related events (SRE) on healthcare resource utilization (HCRU) and costs incurred by patients with bone metastases (BM) from solid tumors (ST), who are therapy-naïve to bone targeting agents (BTAs). Methods German claims data from 01/01/2010 to 30/06/2018 were used to conduct a retrospective comparative cohort analysis of BTA-naive patients with a BM diagnosis and preceding ST diagnosis. HCRU and treatment-related costs were compared in two matched cohorts of patients with and without a history of SREs, defined as pathological fracture, spinal cord compression, surgery to bone and radiation to bone. The first SRE was defined as the patient-individual index date. Conversely, for the non-SRE patients, index dates were assigned randomly. Results In total, 45.20% of 9,832 patients reported experiencing at least one SRE (n = 4444) while 54.80% experienced none (n = 5388); 2,434 pairs of SRE and non-SRE patients were finally matched (mean age: 70.87/71.07 years; females: 39.07%/38.58%). Between SRE and non-SRE cohorts, significant differences in the average number of hospitalization days per patient-year (35.80/30.80) and associated inpatient-care costs (14,199.27€/10,787.31€) were observed. The total cost ratio was 1.16 (p < 0.001) with an average cost breakdown of 23,689.54€ and 20,403.27€ per patient-year in SRE and non-SRE patients. Conclusion The underutilization of BTAs within a clinical setting poses an ongoing challenge in the real-world treatment of BM patients throughout Germany. Ultimately, the economic burden of treating SREs in patients with BM from ST was found to be considerable, resulting in higher direct healthcare costs and increased utilization of inpatient care facilities.

Harnessing the Power of Antibodies to Fight Bone Metastasis

2021 ◽  
Author(s):  
Zeru Tian ◽  
Ling Wu ◽  
Chenfei Yu ◽  
Yuda Chen ◽  
Zhan Xu ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Clinical Success ◽  
Growth Factor Receptor ◽  
Bone Diseases ◽  
Bone Lesions ◽  
Therapeutic Antibodies ◽  
Her2 Positive ◽  
Bone Targeting ◽  
Physical Barriers ◽  
Antibody Conjugation

AbstractOver the past 20 years, antibody-based therapies have proved to be of great value in cancer treatment. Despite the clinical success of these biopharmaceuticals, reaching targets in the bone micro-environment has proved to be difficult perhaps due to the relatively low vascularization of bone tissue and the presence of physical barriers that impair drug penetration. Here, we have used an innovative bone targeting (BonTarg) technology to generate a first-in-class bone-targeting anti-body. Moreover, we have used two xenograft models to demonstrate the enhanced therapeutic efficacy of this bone-targeting antibody against bone metastases, compared to the efficacy of traditional antibodies. Our strategy involves the use of pClick antibody conjugation technology to chemically couple the bone-targeting moiety bisphosphonate to the human epidermal growth factor receptor 2 (HER2)-specific antibody trastuzumab. Bisphosphonate modification of therapeutic antibodies results in delivery of higher conjugate concentrations to the bone metastatic niche, relative to other tissues. In both HER2-positive and negative xenograft mice models, this strategy provides enhanced inhibition of experimental bone metastases as well as multi-organ secondary metastases that arise from the bone lesions. Specific delivery of therapeutic antibodies to the bone therefore represents a promising strategy for the treatment of bone metastatic cancers and other bone diseases.

Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States

2018 ◽  
Vol 27 (2) ◽  
pp. 229-238 ◽  
Author(s):  
Anne M. Butler ◽  
Karynsa Cetin ◽  
Rohini K. Hernandez ◽  
B. Diane Reams ◽  
Robert A. Overman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Bone Metastases ◽  
The United States ◽  
Bone Targeting

NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours

2012 ◽  
Vol 13 (12) ◽  
pp. 1194-1195 ◽  
Author(s):  
Anwar Jilani ◽  
Zoe Garrett ◽  
Frances Sutcliffe ◽  
Andrew Stevens
Keyword(s):  
Bone Metastases ◽  
Solid Tumours ◽  
Nice Guidance ◽  
Skeletal Related Events

scholarly journals Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis

2015 ◽  
Vol 26 (11) ◽  
pp. 2205-2213 ◽  
Author(s):  
M.F.K. Ibrahim ◽  
S. Mazzarello ◽  
R. Shorr ◽  
L. Vandermeer ◽  
C. Jacobs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Bone Metastases ◽  
Meta Analysis ◽  
Standard Of Care ◽  
Bone Targeting

scholarly journals Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis

2013 ◽  
Vol 49 (2) ◽  
pp. 416-430 ◽  
Author(s):  
John A. Ford ◽  
Rob Jones ◽  
Andrew Elders ◽  
Clive Mulatero ◽  
Pamela Royle ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bone Metastases ◽  
Meta Analysis ◽  
Solid Tumours
Sign in / Sign up

Export Citation Format

Share Document